trimethobenzamide

trye-meth-oh-BEN-za-mide

Therapeutic Classification: antiemetics

Pharmacologic Classification: anticholinergics

REMS

Mild to moderate nausea and vomiting.

Inhibits emetic stimulation of the chemoreceptor trigger zone in the medulla.

Therapeutic effects:

Decreased nausea and vomiting.

Absorption: Complete absorption following oral and IM administration.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by the liver; 30–50% excreted unchanged in urine.

Half-Life: 7–9 hr.

(antiemetic effect)

ROUTE	ONSET	PEAK	DURATION
PO	10–40 min	unknown	3–4 hr
IM	15–35 min	unknown	2–3 hr

Contraindicated in:

Hypersensitivity.

Use Cautiously in:

Geri: Appears on Beers list. Potential for extrapyramidal side effects may outweigh potential benefit;
OB: Safety not established;
Pedi: Safety and effectiveness not established.

CV: hypotension

GI: diarrhea, hepatitis

Derm: rashes

Hemat: blood dyscrasias

Local: pain, burning at IM injection site, redness at IM injection site, stinging at IM injection site

Neuro: COMA, SEIZURES, drowsiness, depression, extrapyramidal reactions

PO (Adults ): 300 mg 3–4 times daily.
IM (Adults ): 200 mg 3–4 times daily as needed.

Renal Impairment

(Adults ): CCr ≤70 mL/min—↓ dose or ↑ dosing interval.

(Generic available)

Capsules: 300 mg
Solution for intramuscular injection: 100 mg/mL

Assess patient for nausea and vomiting prior to and 30–60 min following administration.
Assess BP for hypotension following parenteral administration.

PO: Capsules can be opened and contents mixed with food or fluids for patients with difficulty swallowing.
IM: Inject deep into well-developed muscle mass to minimize tissue irritation.
- Trimethobenzamide is not receommended for IV use.

Instruct patient to take medication as directed. Take missed doses as soon as remembered unless almost time for next dose; do not double doses.
Advise patient to make position changes slowly to minimize orthostatic hypotension following parenteral doses.
May cause drowsiness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Caution patient to avoid taking alcohol or other CNS depressants concurrently with this medication.
Instruct patient to notify health care professional promptly if sore throat, fever, unusual weakness or tiredness, tremors, or yellowing of the skin and eyes occurs.

Prevention and relief of nausea and vomiting.

Risk for deficient fluid volume(Indications)
Risk for injury(Side Effects)

NDC Code

42023- Par Pharmaceutical, Inc.
- 42023-118- Tigan
  - 42023-118-01- 1 VIAL, MULTI-DOSE in 1 CARTON (42023-118-01) > 20 mL in 1 VIAL, MULTI-DOSE

42023- Par Pharmaceutical, Inc.
- 42023-119- Tigan
  - 42023-119-25- 25 VIAL, SINGLE-DOSE in 1 TRAY (42023-119-25) > 2 mL in 1 VIAL, SINGLE-DOSE

43386- Lupin Pharmaceuticals,Inc.
- 43386-660- Trimethobenzamide Hydrochloride
  - 43386-660-03- 30 CAPSULE in 1 BOTTLE (43386-660-03)

43386- Lupin Pharmaceuticals,Inc.
- 43386-660- Trimethobenzamide Hydrochloride
  - 43386-660-24- 100 CAPSULE in 1 BOTTLE (43386-660-24)

43386- Lupin Pharmaceuticals,Inc.
- 43386-660- Trimethobenzamide Hydrochloride
  - 43386-660-26- 500 CAPSULE in 1 BOTTLE (43386-660-26)

50090- A-S Medication Solutions
- 50090-2122- Trimethobenzamide Hydrochloride
  - 50090-2122-0- 12 CAPSULE in 1 BOTTLE (50090-2122-0)

52584- General Injectables and Vaccines, Inc
- 52584-119- Tigan
  - 52584-119-25- 1 VIAL, SINGLE-DOSE in 1 BAG (52584-119-25) > 2 mL in 1 VIAL, SINGLE-DOSE

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-01- 100 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-01)

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-03- 250 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-03)

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-05- 500 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-05)

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-06- 60 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-06)

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-07- 30 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-07)

53489- Sun Pharmaceutical Industries, Inc.
- 53489-376- Trimethobenzamide Hydrochloride
  - 53489-376-10- 1000 CAPSULE in 1 BOTTLE, PLASTIC (53489-376-10)

61570- Pfizer Laboratories Div Pfizer Inc
- 61570-079- TIGAN
  - 61570-079-01- 100 CAPSULE in 1 BOTTLE (61570-079-01)

61919- Direct_Rx
- 61919-884- Trimethobenzamide
  - 61919-884-30- 30 CAPSULE in 1 BOTTLE (61919-884-30)

70518- REMEDYREPACK INC.
- 70518-0510- Trimethobenzamide Hydrochloride
  - 70518-0510-0- 10 CAPSULE in 1 BOTTLE, PLASTIC (70518-0510-0)

70518- REMEDYREPACK INC.
- 70518-1225- TIGAN
  - 70518-1225-0- 10 CAPSULE in 1 BOTTLE, PLASTIC (70518-1225-0)

71335- Bryant Ranch Prepack
- 71335-0800- Trimethobenzamide Hydrochloride
  - 71335-0800-1- 10 CAPSULE in 1 BOTTLE (71335-0800-1)

71335- Bryant Ranch Prepack
- 71335-0800- Trimethobenzamide Hydrochloride
  - 71335-0800-2- 15 CAPSULE in 1 BOTTLE (71335-0800-2)

71335- Bryant Ranch Prepack
- 71335-0800- Trimethobenzamide Hydrochloride
  - 71335-0800-3- 30 CAPSULE in 1 BOTTLE (71335-0800-3)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Pot. Nursing Diagnoses ⬆ ⬇

Code ⬆